JP7250679B2 - Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法 - Google Patents

Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法 Download PDF

Info

Publication number
JP7250679B2
JP7250679B2 JP2019537064A JP2019537064A JP7250679B2 JP 7250679 B2 JP7250679 B2 JP 7250679B2 JP 2019537064 A JP2019537064 A JP 2019537064A JP 2019537064 A JP2019537064 A JP 2019537064A JP 7250679 B2 JP7250679 B2 JP 7250679B2
Authority
JP
Japan
Prior art keywords
agonist
conjugate
cancer
composition
acting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019537064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514300A (ja
JP2020514300A5 (https=
Inventor
ゾンシュー レン，
ニール ケー． アナンド，
ハイイン ツァイ，
ボー－リャン デン，
バルチャンドラ ブイ． ジョシ，
ジョナサン ザレフスキー，
宇広 宮崎
サウル キヴィメイ，
Original Assignee
ネクター セラピューティクス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ネクター セラピューティクス filed Critical ネクター セラピューティクス
Publication of JP2020514300A publication Critical patent/JP2020514300A/ja
Publication of JP2020514300A5 publication Critical patent/JP2020514300A5/ja
Priority to JP2023032182A priority Critical patent/JP2023071870A/ja
Application granted granted Critical
Publication of JP7250679B2 publication Critical patent/JP7250679B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019537064A 2017-01-10 2018-01-10 Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法 Active JP7250679B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023032182A JP2023071870A (ja) 2017-01-10 2023-03-02 Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201762444735P 2017-01-10 2017-01-10
US201762444756P 2017-01-10 2017-01-10
US62/444,735 2017-01-10
US62/444,756 2017-01-10
US201762467945P 2017-03-07 2017-03-07
US62/467,945 2017-03-07
US201762488407P 2017-04-21 2017-04-21
US201762488251P 2017-04-21 2017-04-21
US62/488,251 2017-04-21
US62/488,407 2017-04-21
US201762510019P 2017-05-23 2017-05-23
US201762510024P 2017-05-23 2017-05-23
US62/510,019 2017-05-23
US62/510,024 2017-05-23
PCT/US2018/013199 WO2018132496A1 (en) 2017-01-10 2018-01-10 Multi-arm polymer conjugates of tlr agonist compounds and related immunotherapeutic treatment methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023032182A Division JP2023071870A (ja) 2017-01-10 2023-03-02 Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法

Publications (3)

Publication Number Publication Date
JP2020514300A JP2020514300A (ja) 2020-05-21
JP2020514300A5 JP2020514300A5 (https=) 2022-09-02
JP7250679B2 true JP7250679B2 (ja) 2023-04-03

Family

ID=61231306

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019537064A Active JP7250679B2 (ja) 2017-01-10 2018-01-10 Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法
JP2023032182A Withdrawn JP2023071870A (ja) 2017-01-10 2023-03-02 Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023032182A Withdrawn JP2023071870A (ja) 2017-01-10 2023-03-02 Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法

Country Status (10)

Country Link
US (2) US11744898B2 (https=)
EP (1) EP3568162B1 (https=)
JP (2) JP7250679B2 (https=)
KR (1) KR102619747B1 (https=)
CN (1) CN110167598A (https=)
AU (1) AU2018207283C1 (https=)
CA (1) CA3049254A1 (https=)
IL (2) IL297655B2 (https=)
MX (1) MX2019008276A (https=)
WO (1) WO2018132496A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
KR102619747B1 (ko) 2017-01-10 2023-12-29 넥타르 테라퓨틱스 Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
WO2018204528A1 (en) 2017-05-02 2018-11-08 Nektar Therapeutics Immunotherapeutic tumor treatment method
WO2019036031A2 (en) 2017-08-17 2019-02-21 Nektar Therapeutics IMMUNOTHERAPEUTIC METHOD FOR TUMOR TREATMENT
US20210386826A1 (en) 2018-11-05 2021-12-16 Pfizer Inc. Combination for Treating Cancer
US20210355223A1 (en) 2018-11-05 2021-11-18 Pfizer Inc. Combinations for Treating Cancer
CA3125488A1 (en) * 2019-01-04 2020-07-09 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
JP2022521478A (ja) * 2019-02-11 2022-04-08 ザ ハート リサーチ インスティテュート リミテッド 薬剤を担持したプラズマポリマーナノ粒子
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN113966326A (zh) * 2019-04-05 2022-01-21 大日本住友制药株式会社 水溶性佐剂
WO2021202923A1 (en) 2020-04-02 2021-10-07 Nektar Therapeutics Immunomodulator for the prevention and treatment of coronovirus infection and other conditions
CN115997008A (zh) 2020-04-22 2023-04-21 艾欧凡斯生物治疗公司 协调用于患者特异性免疫疗法的细胞的制造的系统和方法
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022098954A1 (en) 2020-11-06 2022-05-12 Nektar Therapeutics Tlr agonist compounds and related cancer immunotherapy methods
EP4259164A1 (en) 2020-12-11 2023-10-18 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2024501845A (ja) 2020-12-31 2024-01-16 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の自動化された産生のためのデバイス及びプロセス
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4301138A2 (en) 2021-03-05 2024-01-10 Iovance Biotherapeutics, Inc. Tumor storage and cell culture compositions
US20240191191A1 (en) 2021-03-19 2024-06-13 Iovance Biotherapeutics, Inc. Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
CA3215830A1 (en) 2021-04-19 2022-10-27 Rafael CUBAS Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
EP4373270A2 (en) 2021-07-22 2024-05-29 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
WO2023039488A1 (en) 2021-09-09 2023-03-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
US20250000903A1 (en) 2021-09-24 2025-01-02 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
CA3243416A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. TUMOR INFILTRATION LYMPHOCYTES MODIFIED TO EXPRESS PAYLOADS
EP4469065A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2025512401A (ja) 2022-04-15 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス
CA3251533A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
WO2024011114A1 (en) 2022-07-06 2024-01-11 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
US20260021181A1 (en) 2022-08-01 2026-01-22 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583889A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
EP4583890A1 (en) 2022-09-09 2025-07-16 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1/tigit talen double knockdown
EP4612277A1 (en) 2022-11-04 2025-09-10 Iovance Biotherapeutics, Inc. Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
JP2025539816A (ja) 2022-11-21 2025-12-09 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の増幅のための２次元プロセス及びそれからの治療法
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025019790A1 (en) 2023-07-19 2025-01-23 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025094035A1 (en) * 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025171182A1 (en) 2024-02-08 2025-08-14 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
WO2026006784A1 (en) 2024-06-28 2026-01-02 Iovance Biotherapeutics, Inc. Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor
WO2026072794A2 (en) 2024-09-26 2026-04-02 Iovance Biotherapeutics, Inc. Expansion processes for til product enriched with neoantigen- reactive t cells (narts)
CN121378484A (zh) * 2024-10-14 2026-01-23 北京大学 抗原结合蛋白及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006249102A (ja) 2001-11-16 2006-09-21 Three M Innovative Properties Co Ｎ−［４−（４−アミノ−２−エチル−１Ｈ−イミダゾ［４，５−ｃ］キノリン−１−イル］ブチル］メタンスルホンアミド、又はその医薬上許容される塩
JP2007532572A (ja) 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
JP2011530597A (ja) 2008-08-11 2011-12-22 ネクター セラピューティックス マルチアームポリマーアルカノエートコンジュゲート
JP2014506116A (ja) 2010-11-12 2014-03-13 ウェルズ ファーゴ バンク ナショナル アソシエイション Ｉｌ−２部分とポリマーとのコンジュゲート
JP2015504881A (ja) 2011-12-20 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 胃腸感染および障害を処置するための医薬組成物および方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
WO2004084949A2 (en) 2003-03-20 2004-10-07 Xencor Generating protein pro-drugs using reversible ppg linkages
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
CA2537336C (en) 2003-09-17 2013-02-26 Nektar Therapeutics Al, Corporation Multi-arm polymer prodrugs
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
HUE025208T2 (en) 2005-06-16 2016-03-29 Nektar Therapeutics Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates
US20080044438A1 (en) 2006-03-17 2008-02-21 Ostroff Gary R Yeast Cell Particles As Oral Delivery Vehicles For Antigens
BRPI1012036A2 (pt) 2009-05-27 2017-10-10 Selecta Biosciences Inc nanocarreadores que possuem componentes com diferentes taxas de liberação
PT2501413T (pt) 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
WO2013166110A1 (en) * 2012-05-02 2013-11-07 Yale University Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
KR102410090B1 (ko) * 2014-02-21 2022-06-16 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제
EP3328418A1 (en) * 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
KR102619747B1 (ko) 2017-01-10 2023-12-29 넥타르 테라퓨틱스 Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006249102A (ja) 2001-11-16 2006-09-21 Three M Innovative Properties Co Ｎ−［４−（４−アミノ−２−エチル−１Ｈ−イミダゾ［４，５−ｃ］キノリン−１−イル］ブチル］メタンスルホンアミド、又はその医薬上許容される塩
JP2007532572A (ja) 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
JP2011530597A (ja) 2008-08-11 2011-12-22 ネクター セラピューティックス マルチアームポリマーアルカノエートコンジュゲート
JP2014506116A (ja) 2010-11-12 2014-03-13 ウェルズ ファーゴ バンク ナショナル アソシエイション Ｉｌ−２部分とポリマーとのコンジュゲート
JP2015504881A (ja) 2011-12-20 2015-02-16 ギリアード サイエンシーズ， インコーポレイテッド 胃腸感染および障害を処置するための医薬組成物および方法

Also Published As

Publication number Publication date
IL297655B1 (en) 2025-07-01
EP3568162B1 (en) 2026-03-18
AU2018207283C1 (en) 2024-05-02
US20210128737A1 (en) 2021-05-06
EP3568162A1 (en) 2019-11-20
CN110167598A (zh) 2019-08-23
US20230372500A1 (en) 2023-11-23
AU2018207283B2 (en) 2024-02-15
US11744898B2 (en) 2023-09-05
JP2020514300A (ja) 2020-05-21
IL267929B2 (en) 2023-03-01
WO2018132496A1 (en) 2018-07-19
IL267929B (en) 2022-11-01
AU2018207283A1 (en) 2019-07-18
MX2019008276A (es) 2019-09-16
JP2023071870A (ja) 2023-05-23
IL297655A (en) 2022-12-01
KR20190104377A (ko) 2019-09-09
IL267929A (en) 2019-09-26
IL297655B2 (en) 2025-11-01
AU2018207283A2 (en) 2019-07-25
US12214045B2 (en) 2025-02-04
KR102619747B1 (ko) 2023-12-29
CA3049254A1 (en) 2018-07-19

Similar Documents

Publication Publication Date Title
JP7250679B2 (ja) Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法
AU2018316694B2 (en) Immunotherapeutic tumor treatment method
JP7165680B2 (ja) 免疫療法的腫瘍治療方法
Lynn et al. Impact of polymer-TLR-7/8 agonist (adjuvant) morphology on the potency and mechanism of CD8 T cell induction
AU2021259426A1 (en) Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer
EP3589303A1 (en) Immunotherapeutic tumor treatment method using an interleukin-2 receptor alpha, beta-selective agonist in combination with adoptive cell transfer therapy
KR20210113272A (ko) 선천 면역 작용제를 위한 지속되는 국소 약물 수준

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220426

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230320

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230322

R150 Certificate of patent or registration of utility model

Ref document number: 7250679

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250